AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23673265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 166
Study 23673265 — intervention group
Group type: COMPARATOR
Intervention: Open surgical release of A1-pulley
Number of subjects: 166
Study 23673265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study 20835573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone morphogenetic proteins associated with collagen membrane (test sites)
Number of subjects: 15
Study 20835573 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane only (control sites)
Number of subjects: 15
Study 18156990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a (40KD) + ribavirin (Peg‐IFN/RBV) for 48 weeks
Number of subjects: 857
Study 18156990 — intervention group
Group type: COMPARATOR
Intervention: Conventional interferon alfa‐2a + ribavirin (IFN/RBV)
Number of subjects: 857
Study 18156990 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a (40KD) + placebo (Peg‐IFN)
Number of subjects: 857
Study 18156990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN/RBV
Number of subjects: 857
Study 16175189 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (110 mg/m² on day 1 and 100 mg/m² on day 8) plus cisplatin (80 mg/m² on day 8)
Number of subjects: 147
Study 16175189 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m² on day 1)
Number of subjects: 147
Study 12970994 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based psychosocial rehabilitation (two outpatient counselling sessions focusing on risk factor reduction and psychosocial adjustment)
Number of subjects: 200
Study 12970994 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study 12970994 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based psychosocial rehabilitation
Number of subjects: 200
Study 10376783 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation (Group A)
Number of subjects: 38
Study 10376783 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation (Group B)
Number of subjects: 38
Study 10376783 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus Zinc supplementation (Group C)
Number of subjects: 38
Study 8808720 — intervention group
Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with complete response, 1 month after operation
Number of subjects: 30
Study 8808720 — intervention group
Group type: COMPARATOR
Intervention: Control group T8 lymphocytes, 1 month after operation
Number of subjects: 30
Study 8808720 — intervention group
Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with partial response, 1 month after operation
Number of subjects: 30
Study 8808720 — intervention group
Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with no effect, 1 month after operation
Number of subjects: 30
Study 8808720 — intervention group
Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in all patients, 3 months after operation
Number of subjects: 30
Study 1417429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 107
Study 1417429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride tricyclic pharmacotherapy
Number of subjects: 107
Study 1417429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy and pharmacotherapy combined
Number of subjects: 107
Study 1417429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study 4043659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 1000 mg/day for 1 month
Number of subjects: 12
Study 4043659 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 12
Study 30938903 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb immobilisation for 2 hours after sheath removal
Number of subjects: 150
Study 30938903 — intervention group
Group type: COMPARATOR
Intervention: Limb immobilisation for 4 hours after sheath removal (Control)
Number of subjects: 150
Study 30175876 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer (SMGT) and intensity-modulated radiotherapy (IMRT)
Number of subjects: 40
Study 27530375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel (IMB) - 3 days treatment cycle
Number of subjects: 22
Study 27530375 — intervention group
Group type: COMPARATOR
Intervention: Daylight photodynamic therapy (dlPDT) - single session
Number of subjects: 22
Study 23983039 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ‐SC (subcutaneous tocilizumab) 162 mg every 2 weeks
Number of subjects: 0
Study 23983039 — intervention group
Group type: COMPARATOR
Intervention: TCZ‐IV (intravenous tocilizumab) 8 mg/kg every 4 weeks
Number of subjects: 0
Study 23983039 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ‐SC
Number of subjects: 0
Study 23983039 — intervention group
Group type: COMPARATOR
Intervention: TCZ‐IV
Number of subjects: 0
Study 23090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity suture training model (synthetic ethylene-vinyl acetate bench model)
Number of subjects: 36
Study 23090233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity suture training model (pig feet skin bench model)
Number of subjects: 36
Study 23090233 — intervention group
Group type: COMPARATOR
Intervention: Theoretical suture training alone (control)
Number of subjects: 36
Study 21542401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin application (Nitroderm)
Number of subjects: 6426
Study 21542401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin application)
Number of subjects: 6426
Study 18722223 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 62
Study 18722223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 15687143 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted group
Number of subjects: 265
Study 15687143 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted group
Number of subjects: 265
Study 12640021 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose recombinant human IL-6 (HiIL-6; n = 6)
Number of subjects: 18
Study 12640021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose IL-6 (LoIL-6; n = 6)
Number of subjects: 18
Study 12640021 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control; n = 6)
Number of subjects: 18
Study 10232639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (25 g)
Number of subjects: 40
Study 10232639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (25 g)
Number of subjects: 40
Study 10232639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (50 g)
Number of subjects: 40
Study 8904629 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 8
Study 8904629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7901582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 1007
Study 3121350 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally after 90 min of insulin infusion)
Number of subjects: 5
Study 3121350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given to control group)
Number of subjects: 5
Study 28455106 — intervention group
Group type: EXPERIMENTAL
Intervention: Late dinner (eating late)
Number of subjects: 0
Study 28455106 — intervention group
Group type: COMPARATOR
Intervention: Early dinner (eating early)
Number of subjects: 0
Study 26351904 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity program (exercising at sport centres at least once per week for 6 months)
Number of subjects: 104
Study 26351904 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity program
Number of subjects: 104
Study 26351904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study 25481340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal technique using an Aintree intubating catheter
Number of subjects: 30
Study 25481340 — intervention group
Group type: COMPARATOR
Intervention: Extraluminal technique using a nasal route alongside the LT
Number of subjects: 30
Study 23490225 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once-daily
Number of subjects: 20
Study 23490225 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 μg twice-daily
Number of subjects: 20
Study 23490225 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 20
Study 23490225 — intervention group
Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 20
Study 21465776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric gaseous cryotherapy using carbon dioxide at -78 degrees C
Number of subjects: 0
Study 19541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral unsaturated fat supplements (90mL of Calogen and 4 capsules of Pikasol)
Number of subjects: 40
Study 19541503 — intervention group
Group type: COMPARATOR
Intervention: No supplements (control)
Number of subjects: 40
Study 16885013 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF3381 (500 mg)
Number of subjects: 27
Study 16885013 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg)
Number of subjects: 27
Study 16885013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15020359 — intervention group
Group type: EXPERIMENTAL
Intervention: T(2) weighted images
Number of subjects: 30
Study 15020359 — intervention group
Group type: COMPARATOR
Intervention: T(1) weighted images
Number of subjects: 30
Study 11831481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide sedation (NO)
Number of subjects: 62
Study 11831481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 62
Study 11831481 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 62
Study 11831481 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 62
Study 10408951 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 32000
Study 10408951 — intervention group
Group type: COMPARATOR
Intervention: Other studies and mechanisms of screening
Number of subjects: 32000
Study 8154645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction treatment
Number of subjects: 14
Study 8154645 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol levels lower than 4.14 mmol/L (160 mg/dL)
Number of subjects: 14
Study 2680584 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg.kg‐1)
Number of subjects: 8
Study 2680584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2680584 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF (inhaled in five successive doses every 15 min)
Number of subjects: 8
Study 2680584 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF
Number of subjects: 8
Study 2680584 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study 769707 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg D(-)penicillamine daily
Number of subjects: 0
Study 769707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg D(-)penicillamine daily
Number of subjects: 0
Study 769707 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of therapy
Number of subjects: 0
Study 769707 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg and 1200 mg D(-)penicillamine
Number of subjects: 0
Study 31377568 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-based intervention (6 household visits over 12 months)
Number of subjects: 2312
Study 31377568 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2312
Study 29122262 — intervention group
Group type: EXPERIMENTAL
Intervention: Geranium aroma (3 drops of geranium essential oil inhaled for 20 minutes a day for 2 days)
Number of subjects: 80
Study 29122262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 drops of placebo inhaled for 20 minutes a day for 2 days)
Number of subjects: 80
Study 24583294 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred stenting
Number of subjects: 101
Study 24583294 — intervention group
Group type: COMPARATOR
Intervention: Immediate stenting
Number of subjects: 101
Study 23684411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once every 12 weeks
Number of subjects: 425
Study 23684411 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg once every 4 weeks
Number of subjects: 425
Study 20368475 — intervention group
Group type: EXPERIMENTAL
Intervention: Joyful music
Number of subjects: 10
Study 20368475 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-provoking music
Number of subjects: 10
Study 18770080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 163
Study 18770080 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 163
Study 18770080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study 15668361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 404
Study 15668361 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 404
Study 15668361 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 404
Study 15668361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib vs Celecoxib
Number of subjects: 404
Study 15668361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib vs Naproxen
Number of subjects: 404
Study 15668361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 404
Study 15668361 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 404
Study 15668361 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 404
Study 12544691 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145
Study 12544691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145
Study 12544691 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145
Study 12544691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-sensitive strains
Number of subjects: 145
Study 12544691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 145
Study 10381247 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais sessions
Number of subjects: 20
Study 10381247 — intervention group
Group type: COMPARATOR
Intervention: Sham sessions
Number of subjects: 20
Study 2112079 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 200
Study 2112079 — intervention group
Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 200
Study 227680 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ionization
Number of subjects: 9
Study 227680 — intervention group
Group type: COMPARATOR
Intervention: Positive ionization
Number of subjects: 9
Study 31296368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 29
Study 31296368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 28370434 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 100
Study 28370434 — intervention group
Group type: COMPARATOR
Intervention: Punch biopsy
Number of subjects: 100
Study 28370434 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 100
Study 25373361 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF treatment (0.2-0.25 mL of bFGF solution applied directly onto the TM once daily until closure)
Number of subjects: 93
Study 25373361 — intervention group
Group type: COMPARATOR
Intervention: Observation group (spontaneous healing)
Number of subjects: 93
Study 25373361 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF treatment (subgroup D, applied after 3 days post-injury)
Number of subjects: 93
Study 25373361 — intervention group
Group type: COMPARATOR
Intervention: Observation group (subgroup A and B)
Number of subjects: 93
Study 25373361 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF treatment (subgroup C and D)
Number of subjects: 93
Study 24933332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1253
Study 24933332 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1253
Study 19720911 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT with tumor bed radiation boost
Number of subjects: 498
Study 19720911 — intervention group
Group type: COMPARATOR
Intervention: BCT without tumor bed radiation boost
Number of subjects: 498
Study 17449934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (7,500 U, twice daily)
Number of subjects: 25
Study 17449934 — intervention group
Group type: COMPARATOR
Intervention: Coumarin derivatives with aspirin
Number of subjects: 25
Study 15200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture with audio
Number of subjects: 59
Study 15200403 — intervention group
Group type: COMPARATOR
Intervention: Online lecture without audio
Number of subjects: 59
Study 12185892 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation of CD4 values based on other health status measures and event status
Number of subjects: 1530
Study 12185892 — intervention group
Group type: COMPARATOR
Intervention: Baseline CD4
Number of subjects: 1530
Study 12185892 — intervention group
Group type: COMPARATOR
Intervention: Last measured CD4 before an event
Number of subjects: 1530
Study 12185892 — intervention group
Group type: COMPARATOR
Intervention: Time-dependent covariate based on carrying the last CD4 value forward
Number of subjects: 1530
Study 9585278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 11
Study 9585278 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-controlled sedation (ACS)
Number of subjects: 11
Study 7651639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate therapy
Number of subjects: 34
Study 7651639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate therapy with ethinyl E2 supplementation
Number of subjects: 34
Study 2644372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent dressing
Number of subjects: 115
Study 2644372 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 115
Study 7422423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis only (Group A)
Number of subjects: 48
Study 7422423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis with biofeedback (Group B)
Number of subjects: 48
Study 7422423 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback only (Group C)
Number of subjects: 48
Study 7422423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (Group A) and Self-hypnosis with biofeedback (Group B)
Number of subjects: 48
Study 30694972 — intervention group
Group type: EXPERIMENTAL
Intervention: LLRE + BFR (low-load resistance exercise at 20% one-repetition maximum)
Number of subjects: 20
Study 30694972 — intervention group
Group type: COMPARATOR
Intervention: REST + BFR
Number of subjects: 20
Study 30694972 — intervention group
Group type: COMPARATOR
Intervention: LLRE
Number of subjects: 20
Study 27916207 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-supplemented medium
Number of subjects: 360
Study 27916207 — intervention group
Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 360
Study 26551369 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial carious dentin removal
Number of subjects: 42
Study 26551369 — intervention group
Group type: COMPARATOR
Intervention: Healthy dentin
Number of subjects: 42
Study 23895188 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth Preparation Programme (BPP)
Number of subjects: 197
Study 23895188 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 197
Study 23192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission B-type natriuretic peptide (BNP) levels
Number of subjects: 979
Study 23192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of BNP to clinical risk prediction model
Number of subjects: 979
Study 23192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of BNP to the Mehran Risk Score
Number of subjects: 979
Study 19851754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 68
Study 19851754 — intervention group
Group type: COMPARATOR
Intervention: Hamstring graft
Number of subjects: 68
Study 18818254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 71
Study 18818254 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 71
Study 15947280 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (cysteinyl leukotriene antagonist)
Number of subjects: 25
Study 15947280 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (antihistamine)
Number of subjects: 25
Study 15947280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15947280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 25
Study 11900269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day for 6 months)
Number of subjects: 44
Study 11900269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9951500 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 26
Study 9951500 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 26
Study 8674923 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 39
Study 2129822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula therapy
Number of subjects: 20